Article Text

Download PDFPDF
Original article
Stability of ARDS subphenotypes over time in two randomised controlled trials
  1. Kevin Delucchi1,
  2. Katie R Famous2,
  3. Lorraine B Ware3,
  4. Polly E Parsons4,
  5. B Taylor Thompson5,
  6. Carolyn S Calfee6
  7. for the ARDS Network
  1. 1 Department of Psychiatry, University of California, San Francisco, California, USA
  2. 2 Critical Care Medicine, Kaiser Permanente Oakland Medical Center, Oakland, California, USA
  3. 3 Departments of Medicine and Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, USA
  4. 4 Department of Medicine, University of Vermont School of Medicine, Burlington, Vermont, USA
  5. 5 Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA
  6. 6 Departments of Medicine and Anesthesia, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, California, USA
  1. Correspondence to Dr Carolyn S Calfee, Departments of Medicine and Anesthesia, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, CA 94143-0111, USA; Carolyn.Calfee{at}ucsf.edu

Footnotes

  • Contributors KD, KRF and CSC drafted the manuscript. KD and KRF performed the statistical analyses. LBW and PEP contributed biomarker measurements. CSC supervised the study design, data interpretation and manuscript preparation. All authors contributed significantly to study design and/or interpretation. All authors made significant intellectual contributions to the final manuscript and approve its submission.

  • Funding NIH grants T32 HL7185-39 and F32 HL129680-01 (KRF); HL103836 and HL112656 (LBW); HL131621 and HL133390 (CSC, KD). NIH/NHLBI ARDS Network contracts: N01-HR 46054-46064.

  • Competing interests CSC has ongoing grant funding from Bayer, prior grant funding from GlaxoSmithKline and consulting for GlaxoSmithKline, Bayer and Boehringer Ingelheim. Other authors have no competing interests to declare.

  • Ethics approval Ethics approval obtained for original studies at each participating institution.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors KD, KRF and CSC drafted the manuscript. KD and KRF performed the statistical analyses. LBW and PEP contributed biomarker measurements. CSC supervised the study design, data interpretation and manuscript preparation. All authors contributed significantly to study design and/or interpretation. All authors made significant intellectual contributions to the final manuscript and approve its submission.

  • Funding NIH grants T32 HL7185-39 and F32 HL129680-01 (KRF); HL103836 and HL112656 (LBW); HL131621 and HL133390 (CSC, KD). NIH/NHLBI ARDS Network contracts: N01-HR 46054-46064.

  • Competing interests CSC has ongoing grant funding from Bayer, prior grant funding from GlaxoSmithKline and consulting for GlaxoSmithKline, Bayer and Boehringer Ingelheim. Other authors have no competing interests to declare.

  • Ethics approval Ethics approval obtained for original studies at each participating institution.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    The Triumvirate